A type C meeting between IDEAYA Biosciences and the FDA has established the design of a phase 3 registrational trial for ...

August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...

The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...

A gynecologic oncologist unpacks shifting cancer trends, HRD and germline testing, screening pitfalls, and where new ...

The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...

ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography ...

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...

Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...

The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...

A prospective Canadian study suggests that moving beyond narrow, cancer-specific molecular panels toward broader genomic ...

Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...